# EXercise and Activin Inhibition to Modulate InflammatioN Effects on Heart Failure and Cognition (EXAMINE-HFC)

> **NCT07202000** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 48 (estimated)

## Conditions studied

- Heart Failure With Preserved Ejection Fraction

## Interventions

- **DRUG:** Activin ligand-trap biological therapy
- **DRUG:** Placebo, Normal Saline

## Key facts

- **NCT ID:** NCT07202000
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-07
- **Final completion:** 2027-08
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-02-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07202000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07202000, "EXercise and Activin Inhibition to Modulate InflammatioN Effects on Heart Failure and Cognition (EXAMINE-HFC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07202000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*